Search

everythinglearnresearchcommunity

for

Search:↓

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.

Some hormone treatments might raise breast cancer risk, while others don't seem to.

The paper concludes that breast cancer treatment involves complex interactions between medical symptoms, patient experiences, and commercial influences, requiring a holistic approach.

Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.

Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.

Docetaxel treatment for breast cancer can cause permanent hair loss.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

Pranic meditation significantly improved mental health and quality of life for breast cancer survivors.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Different types of persistent hair loss after chemotherapy respond differently to treatments.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.

Using certain hair products may increase breast cancer risk in black women.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Reproductive hormones play a crucial role in breast cancer development and treatment challenges.

Low-dose oral minoxidil combined with topical minoxidil improves hair growth in breast cancer patients with therapy-induced hair loss.

Semecarpus anacardium leaf extract fights breast cancer and extends survival in mice.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

Spironolactone use is not linked to an increased risk of breast cancer, but caution is advised for high-risk patients.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.